SCENESSE (Clinuvel Pharmaceuticals Ltd)
Product name
SCENESSE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
144 working days (150)
Active ingredients
afamelanotide acetate
Registration type
NCE/NBE
Indication
SCENESSE (implant) is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).